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Abstract
Background
Observational studies have identified height as a strong risk factor for atrial fibrillation, but
this finding may be limited by residual confounding. We aimed to examine genetic variation
in height within the Mendelian randomization (MR) framework to determine whether height
has a causal effect on risk of atrial fibrillation.
Methods and findings
In summary-level analyses, MR was performed using summary statistics from genome-
wide association studies of height (GIANT/UK Biobank; 693,529 individuals) and atrial fibril-
lation (AFGen; 65,446 cases and 522,744 controls), finding that each 1-SD increase in
genetically predicted height increased the odds of atrial fibrillation (odds ratio [OR] 1.34;
95% CI 1.29 to 1.40; p = 5 × 10−42). This result remained consistent in sensitivity analyses
with MR methods that make different assumptions about the presence of pleiotropy, and
when accounting for the effects of traditional cardiovascular risk factors on atrial fibrillation.
Individual-level phenome-wide association studies of height and a height genetic risk score
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were performed among 6,567 European-ancestry participants of the Penn Medicine Bio-
bank (median age at enrollment 63 years, interquartile range 55–72; 38% female; recruit-
ment 2008–2015), confirming prior observational associations between height and atrial
fibrillation. Individual-level MR confirmed that each 1-SD increase in height increased the
odds of atrial fibrillation, including adjustment for clinical and echocardiographic confound-
ers (OR 1.89; 95% CI 1.50 to 2.40; p = 0.007). The main limitations of this study include
potential bias from pleiotropic effects of genetic variants, and lack of generalizability of indi-
vidual-level findings to non-European populations.
Conclusions
In this study, we observed evidence that height is likely a positive causal risk factor for atrial
fibrillation. Further study is needed to determine whether risk prediction tools including
height or anthropometric risk factors can be used to improve screening and primary preven-
tion of atrial fibrillation, and whether biological pathways involved in height may offer new
targets for treatment of atrial fibrillation.
Author summary
Why was this study done?
• Studies have identified height as a risk factor for atrial fibrillation, a common abnormal
heart rhythm.
• Whether being taller actually elevates risk of atrial fibrillation, or if this association is an
artifact of prior study designs, remains unclear.
What did the researchers do and find?
• We examined randomly allocated genetic variants associated with height within the
Mendelian randomization framework to study the effects of height on risk of atrial
fibrillation.
• Genetic variants associated with taller stature were also associated with increased risk of
atrial fibrillation. This finding was consistent across multiple analysis methods, includ-
ing when accounting for other known atrial fibrillation risk factors.
What do these findings mean?
• Taller individuals are likely to be at increased risk of atrial fibrillation.
• Future research is needed to better define the pathways connecting height to atrial
fibrillation.
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Introduction
Atrial fibrillation is a common cardiac arrhythmia, with a population prevalence of 0.5%,
affecting more than 33 million individuals worldwide [1]. A number of risk factors are associ-
ated with atrial fibrillation, including chronic diseases like chronic kidney disease, heart fail-
ure, thyroid disease, obesity, obstructive sleep apnea, sleep apnea, and valvular heart disease, as
well as cardiac surgery, smoking, and anthropometric factors [2–5]. Recent studies have identi-
fied both common and rare genetic variants at more than 100 independent loci contributing
to the incidence of atrial fibrillation, and heritability is estimated at 20% [6–8]. Even with treat-
ment, affected individuals are at risk of cardioembolic stroke, heart failure, and death [2].
Height has been identified as a risk factor for a number of cardiometabolic diseases, includ-
ing coronary artery disease, atrial fibrillation, and venous thromboembolism [9,10]. The rela-
tionship between height and atrial fibrillation in particular has been identified in large
observational studies, with greater height strongly associated with increased risk of atrial fibril-
lation [4,11–18]. These studies are limited in assessing the causality and potential mediators or
confounders of this association by their observational design, and randomized controlled trials
of anthropometric traits are not feasible. Although a number of factors influence height
including childhood illness/development, diet/nutrition, and socioeconomic status, height has
a strong genetic component. Large genome-wide association studies (GWASs) have provided
heritability estimates of 60%–70%, and have identified more than 700 independent loci that
contribute to height [19–22].
In the current study, we utilize human genetic data within the Mendelian randomization
(MR) framework to evaluate a potential causal association between height and atrial fibrilla-
tion. MR analysis exploits the random assortment of genetic variants during meiosis as an
instrumental variable to estimate the causal relationship between a trait and an outcome of
interest. Here, we use summary data from large, multiethnic GWASs of height (693,529 indi-
viduals) and atrial fibrillation (65,446 cases and 522,744 controls) to estimate the effect of
genetically predicted height on risk of atrial fibrillation [7,19]. We then use participant-level
data from the Penn Medicine Biobank within the observational phenome-wide association
study (PheWAS) framework to identify other clinical associations with height, and within the
single-sample MR framework to further assess the impact of height on atrial fibrillation after
adjustment for clinical risk factors.
Methods
This study is reported per the Strengthening the Reporting of Observational Studies in Epide-
miology (STROBE) guideline (S1 STROBE Checklist). The study did not have a pre-registered
or published analysis plan. All analyses were planned prior to study initiation.
Two-sample MR analysis
Summary-level data for height was obtained from a 2018 meta-analysis of GWASs of height
[19]. This analysis was a fixed-effects meta-analysis combining results from a GWAS of height
performed among 456,426 participants from the UK Biobank (adjusted for age, sex, recruit-
ment center, genotyping batch, and 10 genetic principal components) and results from a 2014
GWAS published by the GIANT (Genetic Investigation of ANthropometric Traits) Consor-
tium, which included 253,288 participants from 79 studies (adjusted for age, sex, and study-
specific covariates). Genetic variants associated with height at genome-wide significance
(p< 5 × 10−8) were then LD-pruned (distance threshold = 10,000 kb, r2 = 0.001) using the
clump_data command in the TwoSampleMR package in R to identify an independent set of
variants to serve as a genetic instrument for height [23]. The independent variants associated
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with height at genome-wide significance (p< 5 × 10−8) were then harmonized with variants
from the 2018 Roselli et al. [7] atrial fibrillation GWAS from the AFGen (Atrial Fibrillation
Genetics) Consortium, using the default settings of the harmonize_data command in the Two-
SampleMR package in R to ensure that effect estimates were aligned to the same allele. This
study included 65,446 atrial fibrillation cases and 522,744 controls from more than 50 studies
(84.2% European, 12.5% Japanese, 2% African American, and 1.3% Brazilian and Hispanic),
including participants from UK Biobank, Biobank Japan, other international biobanks, and
international cardiovascular cohort studies (adjusted for age, sex, and study-specific covari-
ates) [7]. In total, 707 independent SNPs associated with height were available in the atrial
fibrillation outcome GWAS. These 707 SNPs accounted for 11.2% of the variability in height
(S1 Table).
Inverse-variance-weighted 2-sample MR was used as the primary analysis, with weighted
median, MR-Egger, and MR-PRESSO performed as sensitivity analyses to account for poten-
tial violations of the instrumental variable assumptions [24]. Further sensitivity analysis was
performed using a genetic instrument for height constructed excluding any SNPs nominally
(p< 0.05) associated with coronary artery disease, high-density lipoprotein (HDL), low-den-
sity lipoprotein (LDL), total cholesterol, triglycerides, fasting glucose, fasting insulin, diabetes,
BMI, waist-to-hip ratio, and systolic blood pressure, all identified using the MR-Base database
[25–28].
For each variant included in the genetic instruments, variance (R2) was calculated using the
formula R2 = 2 × MAF × (1−MAF) × beta2 (where MAF represents the effect allele frequency
and beta represents the effect estimate of the genetic variant in the exposure GWAS). F-statis-
tics were then calculated for each variant using the formula F ¼ R
2�ðN  2Þ
1  R2 (where R
2 represents
the variance in exposure explained by the genetic variant, and N represents the number of
individuals in the exposure GWAS) to assess the strength of the selected instruments [29]. Bias
due to sample overlap between the exposure and outcome GWASs was estimated and found to
be negligible (S1 Methods) [30]. The estimates for the effect of height on atrial fibrillation are
reported per 1–standard deviation (SD) increase in height. A scaled estimate per 10-cm
increase in height has also been calculated for the main analysis based on the February 2020
UK Biobank population standard deviation of height (9.28 cm).
To account for the possibility that the restrictive genetic instrument may introduce collider
or ascertainment bias by conditioning on associated traits, multivariable MR was performed
using the TwoSampleMR package in R. This method allows the direct effects of multiple traits
on an outcome to be determined jointly. The effect of height on atrial fibrillation was estimated
in analyses that individually adjusted for potential confounders, including coronary artery dis-
ease, HDL, LDL, total cholesterol, triglycerides, fasting glucose, fasting insulin, diabetes, BMI,
waist-to-hip ratio, and systolic blood pressure, using genetic variants obtained from MR-Base
as above. Potential confounders that had significant (p< 0.05) direct effects on atrial fibrilla-
tion in the individual multivariable models were then combined in a final model to jointly esti-
mate their direct effects on atrial fibrillation.
Bidirectional MR was performed to assess for the possibility of reverse causality. A genetic
instrument for atrial fibrillation containing 73 independent, genome-wide significant variants
was constructed using the same methods as for the height instrument. Inverse-variance-
weighted, weighted median, and MR-Egger analyses were performed.
Height genetic risk score
A standardized, weighted genetic risk score (GRS) for height was calculated for each individual
in the Penn Medicine Biobank using imputed dosage information in an additive model,
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weighted by the effect size of each independent (distance threshold = 10,000 kb, r2 = 0.001),
genome-wide significant (p< 5 × 10−8) variant from the 2018 Yengo et al. GWAS of height
[19], using the clump_data command in the TwoSampleMR package in R. Scores were stan-
dardized, centered to mean = 0, and scaled.
PheWAS
PheWASs were performed to identify clinical diagnoses associated both measured height and
the height GRS, using the default setting of the PheWAS package in R [31]. Briefly, interna-
tional classification disease codes obtained from the electronic health record were mapped to
“Phecodes,” and individuals were assigned case/control status or excluded using default map-
ping parameters. Association between height/height GRS and phenotypes was tested using
logistic regression, adjusted for age, age2, sex, and 10 genetic principal components. The 10
genetic principal components included in the PheWAS analysis were selected a priori, without
investigation of the variation of the data. For the more detailed individual-level MR analyses, 6
genetic principal components were identified qualitatively using a scree plot as explaining the
majority of variation in the data (S4 Fig). The Bonferroni method was used to account for mul-
tiple testing (p = 0.05/1,816 phenotypes).
Individual-level MR
To estimate the population-averaged effect of increased height on risk of atrial fibrillation,
individual-level MR was performed using the 2-stage method [32]. This analysis included
6,567 individuals with available height, genotype, and clinical covariate information. The
instrumental variable was a GRS for height, computed from independent, genome-wide signif-
icant variants, weighted by effect on height in the 2018 GIANT/UK Biobank GWAS meta-
analysis. Of the 707 genetic variants included in the main instrumental variable for height in
the 2-sample MR analysis, 695 were available for use in the individual-level analysis (S3 Table).
In the first stage of the 2-stage process, a linear regression was fitted with height as the depen-
dent variable, and the GRS for height as the independent variable, among the subset of individ-
uals without atrial fibrillation, adjusted for age, sex, and 6 genetic principal components. The 6
genetic principal components were selected qualitatively using a scree plot as explaining the
majority of variation in the data (S4 Fig). In the second stage, a logistic regression model with
robust standard errors was fit for both atrial fibrillation cases and controls, incorporating the
fitted values of height from the first stage, adjusted for age, sex, and the 6 genetic principal
components, with atrial fibrillation as the outcome. In additional models, each stage was
adjusted for clinical diagnoses of hypertension, coronary artery disease, heart failure, hyperlip-
idemia, diabetes, chronic kidney disease, stroke, valvular heart disease, sleep apnea, thyroid
disease, cardiac surgery, smoking, and echocardiographic left atrial size to account for poten-
tial cofounders/mediators of the height–atrial fibrillation relationship. These risk factors were
selected for being common cardiometabolic risk factors or having prior associations with atrial
fibrillation [2]. Sensitivity analysis was performed including only individuals who had available
echocardiographic data.
MR assumptions
MR relies on the naturally random assortment of genetic variants at conception to provide
unbiased estimates of the effect of an exposure (in this case height) on an outcome (atrial fibril-
lation). To provide unbiased estimates, MR depends on 3 key assumptions [33]. First, genetic
instruments must be associated with the exposure of interest (relevance assumption). Weak
instruments that are not strongly associated with the exposure of interest may result in biased
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estimates. To estimate the strength of the height genetic instrument, the F-statistic was calcu-
lated (S1 Table). The second assumption is that no confounders of the SNP–outcome associa-
tion are present. This assumption is not readily testable because some confounders may not be
measured, although at both the 2-sample and individual-level the MR analyses were adjusted
for common cardiovascular risk factors. Further, because genetic variants are randomly allo-
cated at conception, confounders of the SNP–outcome association should be distributed across
the population. The third assumption is that the effect of the genetic instrument on atrial fibril-
lation is entirely through the effect on height (exclusion restriction). We performed a PheWAS
using the GRS for height to assess for potentially pleiotropic effects of height. Further, we
applied multiple MR methods including weighted median, MR-Egger, and MR-PRESSO,
which are more robust to the presence of horizontal pleiotropy, a potential violation of the
exclusion restriction assumption [24]. Finally, MR assumes that genetically mediated effects
are similar to exogenous effects. In this case, height is highly heritable, although the effect of
changes in stature related to environmental exposures (e.g., fetal growth restriction, malnutri-
tion) may differ from the genetic effects assessed here.
Penn Medicine Biobank
The Penn Medicine Biobank is a longitudinal genomics and precision medicine study in which
participants consent to linkage of genomic information and biospecimens to the electronic health
record. More than 60,000 individuals are currently enrolled. This study included 6,567 individu-
als of European ancestry (genetically determined) who underwent genotyping and had available
electronic health record data. For individual-level analyses in the Penn Medicine Biobank, contin-
uous demographic variables were summarized by mean and standard deviation, with categorical
variables summarized by count and group percent. The Wilcoxon rank sum test and Fisher’s
exact test, respectively, were used to assess for significant differences between groups.
Phenotype ascertainment
For individual-level analyses in Penn Medicine Biobank, phenotypes were determined by que-
rying the electronic health record. International Classification of Diseases (ICD)–9/10 and
Current Procedural Terminology (CPT) codes, in addition to laboratory measurements and
vital signs, were used to identify height, weight, BMI, smoking status, diagnoses of heart fail-
ure, hypertension, diabetes mellitus, chronic kidney disease, sleep apnea, stroke, thyroid dis-
ease, valvular heart disease, and cardiac surgery. We identified 6,567 participants with
available high-quality genotype and electronic health record phenotype data, with transtho-
racic echocardiogram data available for a subset of 2,842 individuals. Atrial fibrillation was
defined using ICD-9/10 codes 427.31, I48.0, I48.1, I48.2, and I48.91. Atrial fibrillation ascer-
tainment in the 2018 Roselli et al. GWAS meta-analysis was study-specific [7]. Data were
extracted as of January 2017 (S1 Methods).
Ethical approval
The investigators from the Penn Medicine Biobank (MGL, RJ, MV, SSV, YB, MDR, DJR, BFV,
SMD) have received approval from the University of Pennsylvania Institutional Review Board.
No additional approval was required for analyses of publicly available summary statistics.
Statistical analysis
All statistical analyses were performed using R version 3.5.1 [34]. For statistical analyses, p<
0.05 was considered statistically significant.
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Results
Population-level MR
To characterize the relationship between increasing height and risk of atrial fibrillation, we
constructed a genetic instrument for height using 707 independent SNPs associated with
height at a genome-wide level of significance (p< 5 × 10−8), which accounted for 11.2% of the
variability in height (S1 Table). The mean F-statistic was 110 (range 22–948), suggesting the
risk of weak instrument bias was low [30]. We performed 2-sample MR using summary statis-
tics from a GWAS of atrial fibrillation including 65,446 atrial fibrillation cases and 522,744
controls. Inverse-variance-weighted modeling identified a significant association between
increasing height and atrial fibrillation (odds ratio [OR] 1.34 per 1-SD increase in height; 95%
CI 1.29 to 1.40; p = 5 × 10−42) (Fig 1). This corresponds to an OR of 1.37 (95% CI 1.31 to 1.44)
per 10-cm increase in height among UK Biobank participants. The intercept from Egger
Fig 1. Two-sample Mendelian randomization (MR). Two-sample MR was performed using a genetic instrument containing 707 independent SNPs associated with
height. (A) Each point represents the SNP effects on height and atrial fibrillation. Colored lines represent inverse-variance-weighted (red), weighted median (green),
and MR-Egger (blue) estimates of the association between a 1-SD increase in height and risk of atrial fibrillation. (B) Odds ratios (ORs), 95% confidence intervals (CIs),
and p-values for MR estimates.
https://doi.org/10.1371/journal.pmed.1003288.g001
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regression was −0.001 (p = 0.13), thus not providing evidence for significant pleiotropic bias.
Similar estimates were obtained in sensitivity analyses from weighted median, MR-Egger, and
MR-PRESSO models.
An additional genetic instrument for height was constructed, excluding variants nominally
associated (p< 0.05) with potentially pleiotropic risk factors for atrial fibrillation. The selec-
tion of SNPs using a nominal p-value association of 0.05 was an arbitrarily chosen threshold to
more liberally account for potentially pleiotropic effects of height-associated SNPs. The restric-
tive instrument consisted of 224 independent SNPs, in sum explaining 2.8% of the variance in
height (S2 Table). The mean F-statistic was 88 (range 22–867). MR results using this restrictive
genetic instrument were similar (S1 Fig).
We next performed multivariable MR. Height remained significantly associated with atrial
fibrillation after adjustment for the effect of genetic variants separately on each of coronary
artery disease, HDL, LDL, total cholesterol, triglycerides, fasting glucose, fasting insulin, diabe-
tes, BMI, waist-to-hip ratio, and systolic blood pressure (S4 Table). This analysis identified sig-
nificant associations of BMI, systolic blood pressure, total cholesterol, and coronary artery
disease with atrial fibrillation after adjustment for height. The effect of height on risk of atrial
fibrillation was similar in models accounting for these risk factors individually, and in a com-
bined model jointly considering genetic variants associated with height, BMI, systolic blood
pressure, total cholesterol, and coronary artery disease (Fig 2 and S5 Table).
To assess for the possibility of reverse causation, where genetic variants primarily associated
with increased risk of atrial fibrillation may represent invalid instruments for height, a bidirec-
tional MR analysis was performed. Using a genetic instrument including 73 independent,
genome-wide significant variants associated with atrial fibrillation, there was no evidence for a
causal association with height (S2 Fig).
Demographics
Individual-level analysis focused on 6,567 European-ancestry individuals from the Penn Medi-
cine Biobank with available genotype data linked to the electronic health record, recruited
between 2008 and 2015. Individuals with atrial fibrillation were older (mean 66 versus 60
years; p< 0.001) than individuals without atrial fibrillation. Individuals with atrial fibrillation
were taller (mean 174 versus 170 cm; p< 0.001), and significantly more likely to have been
diagnosed with chronic kidney disease, coronary artery disease, heart failure, hyperlipidemia,
hypertension, prior cardiac surgery, sleep apnea, smoking, stroke, or valvular heart disease,
compared to individuals without atrial fibrillation (Table 1 and S6–S8). Among the subset of
Fig 2. Multivariable Mendelian randomization analysis. Multivariable Mendelian randomization was performed to jointly consider the effect of genetic variants for
cardiometabolic traits and height on atrial fibrillation. The effect of a 1-SD increase in height on risk of atrial fibrillation estimated by each model is displayed. ORs per
1-SD increase in height, 95% confidence intervals (CIs), and p-values for Mendelian randomization estimates are displayed.
https://doi.org/10.1371/journal.pmed.1003288.g002
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individuals with echocardiograms, individuals with atrial fibrillation had larger left atrial
diameter (mean 4.39 versus 3.92 cm; p< 0.001).
PheWASs of height and height GRS
To determine the association between genetically predicted height and clinical diagnoses, we
first constructed a GRS for height using weights derived from the 2018 GIANT/UK Biobank
height GWAS meta-analysis. PheWASs were performed to identify clinical diagnoses associ-
ated with both measured height and the height GRS across the Penn Medicine Biobank. Each
1-SD increase in measured height was associated with increased risk of atrial fibrillation (OR
1.55; 95% CI 1.41 to 1.71; p = 3.6 × 10−18) and decreased risk of coronary atherosclerosis (OR
0.66; p = 6.9 × 10−18). Each 1-SD increase in height GRS was associated with increased risk of
atrial fibrillation and flutter (OR 1.16; 95% CI 1.09 to 1.23; p = 7 × 10−6) (Fig 3).
Individual-level MR
Individual-level MR was performed in Penn Medicine Biobank participants to further assess
the association between height and atrial fibrillation. Using the height GRS as an instrumental
variable, height was significantly associated with atrial fibrillation (OR 1.75 per 1-SD increase
in height; 95% CI 1.53 to 2.0; p = 6 × 10−5) after adjusting for age, sex, and 6 genetic principal
components (Fig 4). This corresponds to an OR of 1.66 (95% CI 1.46 to 1.86) per 10-cm
increase in height among Penn Medicine Biobank participants. Results were similar in sex-
stratified analysis. Height remained associated with atrial fibrillation after adjustment for
weight, hypertension, coronary artery disease, heart failure, hyperlipidemia, diabetes, chronic
kidney disease, sleep apnea, stroke, thyroid disease, smoking, cardiac surgery, and valvular
Table 1. Demographics.
Characteristic Statistic No atrial fibrillation
N = 3,538
Atrial fibrillation
N = 3,029
p-Value
Age (years) Mean (SD) 60 (14) 66 (12) <0.001
Sex (female) n (%) 1,577 (45%) 930 (31%) <0.001
BMI (kg/m2) Mean (SD) 29 (6) 29 (6) <0.001
Height (cm) Mean (SD) 170 (11) 174 (11) <0.001
Weight (kg) Mean (SD) 83 (21) 88 (22) <0.001
Hypertension n (%) 1,799 (51%) 2,117 (70%) <0.001
Coronary artery disease n (%) 1,747 (49%) 1,764 (58%) <0.001
Heart failure n (%) 971 (27%) 1,690 (56%) <0.001
Hyperlipidemia n (%) 1,829 (52%) 1,946 (64%) <0.001
Diabetes n (%) 596 (17%) 497 (16%) 0.7
Chronic kidney disease n (%) 400 (11%) 577 (19%) <0.001
Sleep apnea n (%) 411 (12%) 634 (21%) <0.001
Stroke n (%) 575 (16%) 724 (24%) <0.001
Thyroid disease n (%) 71 (2.0%) 78 (2.6%) 0.14
Cardiac surgery n (%) 830 (23%) 2,063 (68%) <0.001
Valve disease n (%) 902 (25%) 1,407 (46%) <0.001
Smoking n (%) 1,654 (47%) 1,526 (50%) 0.004
Left atrial diameter (cm)� Mean (SD) 3.92 (0.76) 4.39 (0.81) <0.001
Demographics of individuals in Penn Medicine Biobank cohort with and without atrial fibrillation.
�Left atrial diameter available for 2,842 participants.
https://doi.org/10.1371/journal.pmed.1003288.t001
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heart disease. After further adjustment for left atrial size, height remained significantly associ-
ated with atrial fibrillation (OR 1.83; 95% CI 1.44 to 2.31; p = 0.01). When individual-level MR
was restricted to the subset of individuals with complete data, the effect estimates were similar,
with modest attenuation with sequential adjustment for clinical risk factors and left atrial size
(S3 Fig).
Discussion
In this study we used both population- and individual-level genetic information to test the
association between height and atrial fibrillation. At the population level, there was a strong
causal association between genetic determinants of height and risk of atrial fibrillation. This
finding was robust to multiple sensitivity analyses of the MR methods and the genetic
Fig 3. Phenome-wide associations of clinical diagnoses with height and height genetic risk score (GRS). Phenome-wide association studies were performed in Penn
Medicine Biobank participants to identify clinical phenotypes associated with increased (A) height and (B) height GRS. The horizontal red line denotes the Bonferroni-
adjusted level of significance (0.05/1,816 phenotypes), the blue line denotes the nominal level of significance (0.05), and triangles denote the direction of association
between increasing height and risk of the phenotype (pointing upward = increased risk; pointing downward = decreased risk).
https://doi.org/10.1371/journal.pmed.1003288.g003
Fig 4. Individual-level instrumental variable analysis. Individual-level instrumental variable analysis was performed in Penn Medicine Biobank participants,
using a weighted genetic risk score for height as an instrumental variable for measured height. The base model was adjusted for age, sex, and 6 genetic principal
components. Model 1 was additionally adjusted for weight, hypertension, coronary artery disease, heart failure, hyperlipidemia, diabetes, chronic kidney disease,
sleep apnea, stroke, thyroid disease, smoking, cardiac surgery, and valvular heart disease. Model 2 was additionally adjusted for left atrial size as measured on
transthoracic echocardiogram. Odds ratios (ORs) are reported per 1-SD increase in height.
https://doi.org/10.1371/journal.pmed.1003288.g004
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instrument for height. Observational analysis at the individual level identified a strong associa-
tion between height and increased risk of atrial fibrillation, and decreased risk of coronary
artery disease. MR analysis at both the population and individual levels suggested that height
remains a causal risk factor for atrial fibrillation even after adjustment for other traditional
risk factors.
Our findings are consistent with prior observational analyses that have identified height as
a risk factor for atrial fibrillation [4,11–18]. These studies, including a large Swedish national
cohort study of 1.5 million military conscripts recruited over the course of 28 years, have con-
sistently identified a strong association between height and atrial fibrillation [4]. Observational
designs have limited these studies, due to the possibility of residual confounding. The Helsinki
Birth Cohort Study partially addressed this limitation by considering the effect of maternal
height on risk of atrial fibrillation in offspring, but was limited by a small, homogenous sample
[35]. We further build on those prior findings using the MR framework, considering both
summary-level and individual-level genetic data, examining genetic variants associated with
height and atrial fibrillation to provide a causal estimate for the effect of increasing height on
risk of atrial fibrillation. Our population-level MR analysis reinforces a prior MR estimate for
association between increasing height and atrial fibrillation (OR 1.33; 95% CI 1.26 to 1.40)
using updated GWAS summary statistics for height and atrial fibrillation [9]. By including a
large multiethnic study of atrial fibrillation, we increase the generalizability of the prior MR
findings, which were limited only to white participants of the UK Biobank.
Several mechanisms have been proposed to explain the relationship between height and
atrial fibrillation. Increased left atrial size is correlated with height, and has been identified as
an independent predictor of atrial fibrillation [17,18,36,37]. Consistent with findings from the
Cardiovascular Health Study, however, we found that the effect of height on risk of atrial fibril-
lation was not attenuated after adjustment for left atrial diameter [14]. It is possible that other,
more nuanced markers of left atrial structure and function that have been associated with
severity of atrial fibrillation, such as left atrial volume index, emptying fraction, expansion
index, and contractile function, may also be affected by height and may better explain the asso-
ciation between height and atrial fibrillation [38]. Similarly, 2-dimensional echocardiography
significantly underestimates left atrial size compared to MRI assessment [39]. Investigation of
these factors in the 2-sample setting is limited by the lack of genetic studies of cardiac struc-
ture/function by echocardiography, MRI, or cardiac CT, and study of these parameters in
large cohorts with genetics and imaging data is warranted. Bioimpedance and dual-energy X-
ray absorptiometry measures of body composition have also been associated with atrial fibrilla-
tion [40]. While the current study focused primarily on common cardiometabolic risk factors
used in clinical practice, the possibility remains that more advanced anthropometric screening
beyond height, weight, body mass index, and waist-to-hip ratio may explain some of the effect
of increased height on atrial fibrillation.
MR has previously identified an association between shorter stature and increased risk of
coronary artery disease, mediated in part by increases in LDL cholesterol and triglyceride lev-
els [10]. Our PheWAS of measured height similarly identified an association between height
and decreased risk of coronary artery disease, and our PheWAS of a height GRS identified a
nominally (p< 0.05) protective association between height and coronary artery disease. In the
current MR analysis, we were unable to detect significant associations between these lipid traits
and risk of atrial fibrillation when considered in multivariable models alongside height. Simi-
larly, in multivariable models considering height alongside common cardiometabolic risk fac-
tors for atrial fibrillation, effect estimates were all similar, suggesting these factors may not
substantially mediate the effect of height on risk of atrial fibrillation.
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Although we detected no evidence of horizontal pleiotropy and our results remained robust
to extensive sensitivity analyses, height is a highly polygenic trait, and the possibility remains
that pleiotropic pathways mediate the association between height and atrial fibrillation. A
recent GWAS found genes at atrial-fibrillation-associated loci to be enriched in pathways
important for tissue formation [41]. Coupled with the finding that genes at height-associated
loci are enriched for cardiovascular and endocrine tissue types, these results raise the possibil-
ity of a more complex shared genetic architecture affecting both height and atrial fibrillation
[22]. Thus, we cannot exclude the possibility that genetic variants broadly associated with
growth and development may simultaneously affect height and establish structural cardiovas-
cular changes that may predispose to atrial fibrillation.
The findings of this study have several clinical implications. Anthropometric characteristics
have been included in clinical models that predict incident atrial fibrillation, including BMI in
a model derived from the Framingham Heart Study, and height in the CHARGE-AF (Cohorts
for Heart and Aging Research in Genomic Epidemiology–Atrial Fibrillation) model from the
CHARGE-AF Consortium [42–44]. While height is not a readily modifiable risk factor, the
recognition that taller individuals have increased risk of atrial fibrillation may prompt more
aggressive management of modifiable cardiovascular risk factors like overweight/obesity, pre-
diabetes/diabetes, hypertension, and alcohol/tobacco use. As both height and atrial fibrillation
are heritable, it is possible that height might act as a surrogate for family history of atrial fibril-
lation when this information is not readily available. Further study may clarify the risks of inci-
dent atrial fibrillation attributable to height and family history. Similarly, further mechanistic
investigation of the height–atrial fibrillation link may identify novel modifiable pathways for
intervention. Future study is needed to determine whether risk prediction tools including
height or other anthropometric factors can be used to improve screening and primary preven-
tion of atrial fibrillation.
Our study has several limitations. First, observational analyses from the Penn Medicine Bio-
bank may not be generalizable, as this population represents a cohort within a single academic
health system. Second, despite our use of multiethnic GWASs of height and atrial fibrillation,
the underlying studies focused primarily on individuals of European ancestry. Genetic studies
in broader populations are warranted to further improve the generalizability of these findings.
Third, our population-level MR analyses relied on publicly available summary statistics that
contain some overlapping samples/cohorts. Two-sample MR tends to bias the causal effect
estimates to the null, but sample overlap may make the estimate susceptible to weak instru-
ment bias. In this study, however, despite overlapping cohorts, simulation suggests that the
large sample sizes of the height and atrial fibrillation GWASs, and large F-statistics, make the
risk of weak instrument bias low [30].
In conclusion, we find that increased height is associated with increased risk of atrial fibril-
lation, and this relationship is likely to be causal. These results raise the possibility of investi-
gating height/growth-related pathways as a means for gaining novel mechanistic insights into
atrial fibrillation, as well as the possibility of incorporating height into larger targeted screening
strategies for atrial fibrillation.
Supporting information
S1 Fig. Two-sample MR sensitivity analysis. Two-sample MR was performed using a genetic
instrument containing 224 independent SNPs associated with height, excluding SNPs nomi-
nally associated (p< 0.05) with traditional atrial fibrillation risk factors: coronary artery dis-
ease, HDL, LDL, total cholesterol, triglycerides, fasting glucose, fasting insulin, diabetes, BMI,
waist-to-hip ratio, and systolic blood pressure. (A) Each point represents the SNP effects on
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height and atrial fibrillation. Colored lines represent inverse-variance-weighted (red),
weighted median (green), and MR-Egger (blue) estimates of the association between a 1-SD
increase in height and risk of atrial fibrillation. (B) Odds ratios (ORs), 95% confidence inter-
vals (CIs), and p-values for MR estimates.
(TIF)
S2 Fig. Two-sample MR directionality sensitivity analysis. Two-sample MR was performed
using a genetic instrument containing 73 independent SNPs associated with atrial fibrillation.
(A) Each point represents the SNP effects on atrial fibrillation and height. Colored lines repre-
sent inverse-variance-weighted (red), weighted median (green), and MR-Egger (blue) esti-
mates of the association between a 1-SD increase in height and risk of atrial fibrillation. (B)
Odds ratios (ORs), 95% confidence intervals (CIs), and p-values for MR estimates.
(TIF)
S3 Fig. Individual MR sensitivity analysis. Individual-level instrumental variable analysis was
performed in the subset of Penn Medicine Biobank participants with clinically obtained echo-
cardiogram data, using a GRS for height as an instrumental variable for measured height. The
base model was adjusted for age, sex, and 6 genetic principal components. Model 1 was addi-
tionally adjusted for weight, hypertension, coronary artery disease, heart failure, hyperlipid-
emia, diabetes, chronic kidney disease, sleep apnea, stroke, thyroid disease, smoking, cardiac
surgery, and valvular heart disease. Model 2 was additionally adjusted for left atrial size as mea-
sured on transthoracic echocardiogram. Odds ratios (ORs) are reported per 1-SD increase in
height.
(TIF)
S4 Fig. Genetic principal component scree plot for Penn Medicine Biobank. Proportion of
variance explained for each genetic principal component among European-ancestry partici-
pants of Penn Medicine Biobank.
(TIF)
S1 Methods. Supplemental methods.
(DOCX)
S1 STROBE Checklist. STROBE checklist.
(DOCX)
S1 Table. Full genetic instrument for height used in 2-sample MR analysis including inde-
pendent (distance threshold = 10,000 kb, r2 = 0.001), genome-wide significant
(p< 5 × 10−8) variants.
(XLSX)
S2 Table. Restrictive genetic instrument for height used in 2-sample MR analysis including
independent (distance threshold = 10,000 kb, r2 = 0.001), genome-wide significant
(p< 5 × 10−8) variants, excluding those SNPs nominally (p< 0.05) associated with coro-
nary artery disease, HDL, LDL, total cholesterol, triglycerides, fasting glucose, fasting
insulin, diabetes, BMI, waist-to-hip ratio, and systolic blood pressure in the MR-Base data-
base.
(XLSX)
S3 Table. Full genetic instrument for height used in individual-level MR analysis including
independent (distance threshold = 10,000 kb, r2 = 0.001), genome-wide significant
(p< 5 × 10−8) variants.
(XLSX)
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S4 Table. Results of bivariate multivariable MR analysis considering the effect of height
and each of coronary artery disease, HDL, LDL, total cholesterol, triglycerides, fasting glu-
cose, fasting insulin, diabetes, BMI, waist-to-hip ratio, and systolic blood pressure on atrial
fibrillation.
(XLSX)
S5 Table. Results of combined multivariable MR analysis considering the effects of height,
body mass index, total cholesterol, systolic blood pressure, and coronary heart disease.
(XLSX)
S6 Table. Summary demographics for Penn Medicine Biobank participants overall.
(XLSX)
S7 Table. Summary demographics for Penn Medicine Biobank participants stratified by
quartile of height GRS.
(XLSX)
S8 Table. Summary demographics for Penn Medicine Biobank participants limited to sub-
set of individuals with complete phenotype and echocardiographic data.
(XLSX)
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